METHODS We prospectively enrolled STEMI patients undergoing primary PCI, whom were treated with clopidogrel (600 mg loading and 75 mg QD maintenance: n ¼ 105) or ticagrelor (180 mg loading and 90 mg bid maintenance: n ¼ 64) on top of aspirin. We serially measured platelet reactivity (using VerifyNow assay: pre-PCI, post-PCI, and 1-month follow-up), hs-CRP (pre-PCI, post-PCI, and 1-month follow-up), fibrinogen (pre-PCI and 1month follow-up), vascular function (using brachial-ankle pulse wave velocity [baPWV]: post-PCI and 1-month follow-up) and LV remodeling index (using transthoracic echocardiography: post-PCI and 1-month follow-up). Abstract Withdrawn
RESULTS Baseline demographics and laboratory measurements were well balanced between the treatments. Compared with clopidogrel treatment, ticagrelor treatment showed the lower levels of platelet reactivity from pre-PCI phase (all p values 0.034) (Table) . At 1-month follow-up, ticagrelor treatment sufficiently inhibited ADP-induced platelet reactivity (mostly less than 100 PRU). However, there were no differences in terms with hs-CRP level, baPWV and LV remodeling index between the treatments. Interestingly, ticagrelor versus clopidogrel reduced thrombin-mediated platelet reactivity ( CONCLUSIONS After the short-term treatment with ticagrelor versus clopidogrel, its strong inhibition of platelet activation is not associated with inflammation, vascular function and LV remodeling process in STEMI patients. Beneficial role of ticagrelor needs to be evaluated in randomized clinical trials after long-term treatment. who underwent a successful PCI were enrolled. The study population underwent a successful PCI for a totally occluded IRA. They were divided into two groups according to whether they were prescribed RAS inhibitors at the time of discharge or not: group I (RAS inhibition, n¼556), and group II (No RAS inhibition, n¼113) .
RESULTS During the one-year follow-up, major adverse cardiac events (MACE), which consist of cardiac death and MI, occurred in 71 patients (10.6%). There were significantly reduced incidences of MACE in the group I [hazard ratio (HR) ¼ 0.34, 95% CI (confidence interval) 0.199 -0.588, p¼0.001]. In subgroup analyses, RAS inhibition was beneficial in patients with male gender, history of hypertension or diabetes mellitus, and even in patients with left ventricular ejection fraction (LVEF) !40%. In the baseline and follow-up echocardiographic data, benefit in changes of LVEF and left ventricular endsystolic volume was noted in the group I.
Comparison between baseline and follow-up echocardiographic data. CONCLUSIONS In latecomers with acute MI, RAS inhibition improved long-term clinical outcomes after a successful PCI, even in patients with low risk who had relatively preserved LVEF.
